General Information of Drug (ID: DMHRZ2V)

Drug Name
3-acetyl-11-keto-ursolic acid Drug Info
Synonyms
11-OXOURSOLIC ACID ACETATE; CHEMBL601891; 3-acetyl-11-keto-ursolic acid; NSC33403; AC1L5RI4; 3-O-acetyl-11-oxoursolic acid; MolPort-044-649-591; NSC-33403; BDBM50307109; AKOS016036264; 35959-01-4; (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bS)-10-acetyloxy-1,2,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,5,6,6a,7,8,8a,10,11,12,14b-tetradecahydropicene-4a-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
234102
CAS Number
CAS 35959-01-4
TTD Drug ID
DMHRZ2V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GLYCYRRHIZIN DM8M2N3 Influenza virus infection 1E30-1E32 Phase 3 [2]
BVT.2733 DM6RUKX Lupus 4A40 Phase 3 [3]
INCB13739 DMLQ3PO Type-2 diabetes 5A11 Phase 2a [4]
URSOLIC ACID DM4SOAW Metabolic syndrome x 5C50-5D2Z Phase 2 [1]
JTT-654 DM50M2R Type-2 diabetes 5A11 Phase 2 [5]
RG-4929 DMT4QRD Metabolic disorder 5C50-5D2Z Phase 2 [5]
BMS-770767 DMTVGY7 Hypercholesterolaemia 5C80.0 Phase 2 [5]
UE-2343 DMIERPK Alzheimer disease 8A20 Phase 2 [6]
AZD-4017 DML9M5S Ocular hypertension 9C61.01 Phase 2 [5]
Xanamem DM580GT Alzheimer disease 8A20 Phase 1/2 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) TTN7BL9 DHI1_HUMAN Inhibitor [1]

References

1 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
2 Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
3 Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
4 Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
5 New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.